 Westport, CT, April 13, 2021 GLOBE NEWSWIRE -- BioSig Technologies, Inc. NASDAQ: BSGM BioSig or the Company, a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced it completed enrollment in the PURE EP 2.0 clinical trial. 